CORDIS
EU research results

CORDIS

English EN
European vaccine and microbicides enterprise

European vaccine and microbicides enterprise

Objective

The successful development of preventative strategies against HIV-1 (microbicides, vaccines or their combined effects) would provide a pivotal turning point in global efforts to combat the pandemic spread of AIDS providing an incalculable impact on solving societal problems associated with this disease.
The principal aim of this proposal is to bring together EU scientists from both microbicide and vaccine fields to embrace a coordinated approach to HIV-1 prevention research. Partners in the EUROPRISE consortium represent 14 projects funded by the European Commission in the sixth Framework as well as one project funded by the Gates Foundation. These projects involve 132 institutions from 22 countries. In this respect, EUROPRISE is the first organisation, both in Europe and internationally to deliberately bring these groups together in a truly integrated fashion. EUROPRISE will promote an integrated program of research, coordinating a wide portfolio of activities encompassing the whole pipeline of vaccine and microbicide development from early discovery through to early clinical trials. This unique approach places the Network at the international forefront of understanding the interface between these two technologies, pursing a critical path to the development of effective HIV-1 prevention strategies.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

Address

Cranmer Terrace
--- London

United Kingdom

Administrative Contact

Robin SHATTOCK (Professor)

Participants (38)

Sort alphabetically

Expand all

KAROLINSKA INSTITUTET

Sweden

NOVARTIS VACCINES AND DIAGNOSTIC SRL

Italy

ALTA SRL

Italy

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium

POLYMUN SCIENTIFIC, IMMUNBIOLOGISCHE FORSCHUNG GMBH

Austria

KING'S COLLEGE, LONDON

United Kingdom

UNIVERSITÀ DI NAPOLI FEDERICO II

Italy

RUHR-UNIVERSITAET BOCHUM

Germany

THE HEALTH PROTECTION AGENCY

United Kingdom

UNIVERSITY COLLEGE LONDON

United Kingdom

IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

United Kingdom

INSTITUUT VOOR TROPISCHE GENEESKUNDE

Belgium

MEDICAL RESEARCH COUNCIL

United Kingdom

FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

Italy

COMMISSARIAT À L?ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES

France

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

UNIVERSITY OF YORK

United Kingdom

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

DEUTSCHES PRIMATENZENTRUM GMBH

Germany

LUND UNIVERSITY

Sweden

INSTITUT PASTEUR

France

ACADEMIC MEDICAL CENTER OF THE UNIVERSITY OF AMSTERDAM

Netherlands

INSTITUTO DE SALUD CARLOS III

Spain

ROBERT KOCH-INSTITUT

Germany

IVANOVSKY INSTITUTE OF VIROLOGY, RUSSIAN ACADEMY OF MEDICAL SCIENCE

Russia

MABTECH AB

Sweden

EUROPEAN AIDS TREATMENT GROUP E.V.

Belgium

UNIVERSITE DE STRASBOURG

France

UNIVERSITY OF REGENSBURG

Germany

SANOFI PASTEUR S.A.

France

THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

ISTITUTO SUPERIORE DI SANITA

Italy

OSPEDALE PEDIATRICO BAMBINO GESU

Italy

UNIVERSITY OF UTRECHT

Netherlands

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

UNIVERSITA DEGLI STUDI DI CAGLIARI

Italy

UNIVERSITA DEGLI STUDI DI SIENA

Italy

UNIVERSITA DEGLI STUDI DI VERONA

Italy

Project information

Grant agreement ID: 37611

  • Start date

    1 January 2007

  • End date

    30 June 2012

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 15 500 000

  • EU contribution

    € 20 095 505

Coordinated by:

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

United Kingdom